Integrating traditional therapies into palliative oncology care: Insights from bottle gourd moxibustion and umbilical therapy

Abstract

Cancer-related incomplete bowel obstruction presents a significant challenge in oncology, with conventional palliative treatments often proving insufficient in alleviating symptoms and controlling inflammation. In this issue, Wu et al report that bottle gourd moxibustion combined with umbilical therapy (BGM-UT) leads to notable improvement in gastrointestinal recovery, reduced opioid dependency, and lower key inflammatory cytokine levels. These findings suggest that BGM-UT may help interrupt the cycle of pain, opioid side effects, and bowel dysfunction, and could be associated with systemic anti-inflammatory effects. Beyond its clinical implications, this work highlights the possibility that evidence-supported traditional therapies may be integrated into modern oncology care. However, the retrospective, single-center design highlights the need for future prospective, multicenter trials and mechanistic studies. If validated in future studies, BGM-UT may emerge as a promising complementary treatment, offering a potentially less invasive and patient-centered approach that warrants further scientific evaluation.

Key Words: Cancer-related incomplete bowel obstruction; Palliative care; Bottle gourd moxibustion; Umbilical therapy; Integrative medicine

Core Tip: Cancer-related incomplete bowel obstruction remains a major challenge in palliative oncology. Wu et al demonstrate that bottle gourd moxibustion combined with umbilical therapy can enhance gastrointestinal recovery, reduce opioid dependence, and modulate inflammatory cytokines in patients with advanced malignancies. By integrating traditional Chinese medicine with modern oncology, this low-risk and holistic intervention may provide a potential strategy to improve symptom control and quality of life. These findings suggest that external therapies targeting inflammation and neuroimmune pathways may expand supportive care options in palliative cancer management.

TO THE EDITOR

Cancer-related incomplete bowel obstruction remains one of the most distressing and complex complications in advanced malignancies. Conventional palliative strategies often reveal significant limitations: Surgery is frequently contraindicated, opioids can exacerbate constipation and sedation, and persistent chronic systemic inflammation further impairs patients’ quality of life[1]. There is thus a pressing need for low-risk, holistic, interventions that effectively address both symptoms and underlying pathophysiology.

STUDY HIGHLIGHTS AND EVIDENCE

In this issue, Wu et al[2] provide valuable evidence supporting a novel integrative approach bottle gourd moxibustion combined with umbilical therapy (BGM-UT) which demonstrates significant benefits in symptom relief, opioid reduction, and modulation of inflammatory cytokines. In a retrospective cohort of 109 patients, the addition of BGM-UT to standard care not only accelerated gastrointestinal recovery but also reduced serum interleukin-6, tumor necrosis factor-α, and C-reactive protein. Importantly, these biochemical improvements correlated with faster restoration of bowel function, suggesting that anti-inflammatory modulation may underpin the observed clinical efficacy. The reduced opioid requirements suggest that BGM-UT may play a role in interrupting the cycle of pain, opioid-related side effects, and bowel dysfunction.

SCIENTIFIC RATIONALE

Building on these clinical observations, a biological rationale may help contextualize the potential mechanisms involved. Beyond clinical outcomes, these findings invite a re-evaluation of the current framework for symptom management in palliative oncology. Whereas the prevailing paradigm often prioritizes pharmacological control over physiological restoration, this study suggests that external therapies targeting systemic inflammation and neuromodulation may help reestablish internal homeostasis, thereby addressing both symptoms and their underlying biological milieu.

These results align with a growing body of literature on integrative oncology. Traditional Chinese medicine (TCM) has long emphasized restoring systemic balance through local stimulation and energy regulation. Moxibustion, in particular, combines thermal, infrared, and phytochemical effects that may modulate neuroimmune signaling, improve microcirculation, and attenuate inflammation[3-5]. The umbilical region-with its rich vascular and neural networks-may serve as a strategic target for transdermal absorption and neurovisceral communication, potentially amplifying the therapeutic effects of the combined regimen[6]. In the study by Wu et al[2], the umbilical therapy component incorporated a herbal navel powder composed of raw rhubarb and magnolia bark, covered with heated ginger slices. This indicates that the intervention may exert effects not only through thermal and neuromodulatory pathways but also through localized biochemical activity or limited transdermal interaction of herbal constituents, which could contribute to the observed anti-inflammatory responses. This view is supported by anatomical imaging studies revealing abundant perfusion in the umbilical region[7].

From a mechanistic standpoint, recent advances in neuroimmunology and bioelectronic medicine provide a plausible framework for such interventions. Cutaneous thermal stimulation has been shown to influence vagal tone and cytokine expression, linking sensory input and systemic immune modulation[8,9]. This aligns with the TCM principle of “treating the interior through external pathways”. In this context, Wu et al’s study[2] not only validates a traditional therapy but also extends contemporary understanding of neuroimmune regulation in palliative care.

LIMITATIONS AND FUTURE DIRECTIONS

Several questions remain, however. The retrospective design precludes causal inference, and the single-center setting may limit generalizability. Although the observed cytokine reductions are promising, the underlying mechanisms are still unclear: Are these effects mediated primarily through neuroimmune pathways, thermal modulation, or herbal pharmacology? Addressing these questions will require prospective, multicenter trials with translational studies exploring molecular mechanisms.

CONCLUSION

Ultimately, this study reflects a broader shift in cancer care: From a narrow focus on disease eradication to a more holistic pursuit of patient-centered outcomes. As oncology increasingly embraces integrative models, therapies like BGM-UT with their favorable safety profile, ease of use, and multidimensional benefits deserve serious consideration. That said, their integration into mainstream practice should be guided by robust evidence, ensuring that enthusiasm does not outpace scientific validation. Wu et al[2] remind us that the future of oncology lies not in discarding tradition, but in examining it with modern tools-validating what works, refining what shows promise, and discarding what does not. If confirmed in future studies, BGM-UT could become a useful addition to supportive oncology care, offering a potentially less invasive option that warrants continued scientific evaluation.